Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 46 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Double shock Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

AB103 Peptide Antagonist in Healthy Volunteers

NCT01166984
View directory record Official record
Conditions
Healthy Volunteer Safety Study
Interventions
AB103, Placebo
Drug
Lead sponsor
Atox Bio Ltd
Industry
Eligibility
18 Years to 40 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 21, 2026, 6:09 PM EDT
Terminated Early Phase 1 Interventional

Dual Versus Single Shock for Cardioversion of Atrial Fibrillation

NCT03943693
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Double shock, Single shock
Device
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 21, 2026, 6:09 PM EDT
Completed Phase 1 Interventional

Alirocumab in Patients with Sepsis

NCT05469347
View directory record Official record
Conditions
Sepsis
Interventions
Alirocumab, Placebo
Drug
Lead sponsor
Jonathan Sevransky
Other
Eligibility
18 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 21, 2026, 6:09 PM EDT
Recruiting Phase 4 Interventional

Vasoactive Drugs in Intensive Care Unit

NCT02118467
View directory record Official record
Conditions
Shock
Interventions
Norepinephrine, Epinephrine, Phenylephrine, Vasopressin
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
836 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 21, 2026, 6:09 PM EDT
Not listed Phase 3 Interventional

A Comparison of the dermaPACE® (Pulsed Acoustic Cellular Expression) Device in Conjunction With Standard of Care Versus Standard of Care Alone in the Treatment of Diabetic Foot Ulcers

NCT01824407
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
Electrohydraulic-generated shock wave, Sham device plus standard of care
Device
Lead sponsor
SANUWAVE, Inc.
Industry
Eligibility
22 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
18
States / cities
Phoenix, Arizona • Tucson, Arizona • Long Beach, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2014 · Synced Oct 21, 2026, 6:09 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Vitamin C and Septic Shock

NCT03338569
View directory record Official record
Conditions
Septic Shock, Sepsis
Interventions
Vitamin C, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Oct 21, 2026, 6:09 PM EDT
Terminated Phase 2 Interventional Results available

Thiamine vs. Placebo to Increase Oxygen Consumption After Cardiac Arrest

NCT02974257
View directory record Official record
Conditions
Cardiac Arrest, Shock, Lactic Acidosis, Thiamin Deficiency
Interventions
Thiamine, placebo
Drug · Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Oct 21, 2026, 6:09 PM EDT
Terminated Phase 3 Interventional

A Study of the Safety and Efficacy of Nitric Oxide Reduction in Patients With Cardiogenic Shock After a Heart Attack

NCT00112281
View directory record Official record
Conditions
Shock, Cardiogenic
Interventions
Tilarginine Acetate Injection intravenous infusion
Drug
Lead sponsor
Arginox Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
658 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
83
States / cities
Mobile, Alabama • Fort Smith, Arizona • Mesa, Arizona + 68 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2006 · Synced Oct 21, 2026, 6:09 PM EDT
Withdrawn Phase 1 Interventional

Thiamine Supplementation in Patients With Septic Shock

NCT03122678
View directory record Official record
Conditions
Septic Shock, Shock, Septic, Lactic Acidosis, Thiamine Deficiency
Interventions
Thiamine, Placebos
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Mar 15, 2019 · Synced Oct 21, 2026, 6:09 PM EDT
Completed Phase 2 Interventional

A Safety and Efficacy Study of Intravenous E5564 in Patients With Severe Sepsis

NCT00046072
View directory record Official record
Conditions
Sepsis, Shock, Septic, Sepsis Syndrome, Septicemia, Infection
Interventions
E5564
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
17
States / cities
Mobile, Alabama • San Diego, California • Santa Barbara, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2005 · Synced Oct 21, 2026, 6:09 PM EDT
Completed Phase 1 Interventional Results available

A Study of Nivolumab Safety and Pharmacokinetics in Patients With Severe Sepsis or Septic Shock.

NCT02960854
View directory record Official record
Conditions
Severe Sepsis
Interventions
Nivolumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
16
States / cities
Sacramento, California • Colorado Springs, Colorado • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 21, 2026, 6:09 PM EDT
Completed Phase 2 Interventional

The Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock

NCT04325035
View directory record Official record
Conditions
Cardiogenic Shock
Interventions
Istaroxime, Placebo
Drug
Lead sponsor
Windtree Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 21, 2026, 6:09 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Efficacy of Vitamin D Supplementation to Sustain Performance Outcomes

NCT07654777
View directory record Official record
Conditions
Acute Stress Reaction
Interventions
Vitamin D3 (Cholecalciferol), Oral Placebo Tablet
Dietary Supplement
Lead sponsor
Walter Reed Army Institute of Research (WRAIR)
Federal
Eligibility
18 Years to 40 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 21, 2026, 6:09 PM EDT
Completed Phase 2 Interventional Results available

Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Participants With Recurrent Genital Herpes

NCT01687595
View directory record Official record
Conditions
Herpes Simplex Type 2
Interventions
HerpV and QS-21, Placebo
Drug
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
5
States / cities
Portland, Oregon • Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Oct 21, 2026, 6:09 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

RCT Comparing ESWT With PRP for Plantar Fasciitis in High Demand Cohort

NCT02668510
View directory record Official record
Conditions
Fasciitis, Plantar
Interventions
platelet rich plasma, Normal saline
Biological · Drug
Lead sponsor
Edna Rath
Federal
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 21, 2026, 6:09 PM EDT
Active, not recruiting Not applicable Interventional

Safety and Effectiveness of the Genio® bilAteral Stimulation for Treatment of Complete Concentric CollapsE and OSA.

NCT05592002
View directory record Official record
Conditions
Sleep Apnea, Obstructive
Interventions
Genio System
Device
Lead sponsor
Nyxoah S.A.
Industry
Eligibility
22 Years to 75 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
16
States / cities
Colorado Springs, Colorado • Boca Raton, Florida • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Oct 21, 2026, 6:09 PM EDT
Not listed Not applicable Interventional

Single vs. Dual-DCCV in Obese Patients

NCT04539158
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Direct Current Cardioversion
Device
Lead sponsor
Dr. Daniel P Morin, MD MPH FHRS
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Gretna, Louisiana • New Orleans, Louisiana • Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 30, 2023 · Synced Oct 21, 2026, 6:09 PM EDT
Terminated Early Phase 1 Interventional Results available

Low Dose Vasopressin in Traumatic Shock

NCT00420407
View directory record Official record
Conditions
Injuries, Shock, Traumatic
Interventions
normal saline control, vasopressin
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Oct 21, 2026, 6:09 PM EDT
Completed Phase 2 Interventional Results available

AZD9773 Dose Escalation Study

NCT00615017
View directory record Official record
Conditions
Severe Sepsis
Interventions
AZD9773 (CytoFab), Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
26
States / cities
Birmingham, Alabama • Newark, Delaware • Bay Pines, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2013 · Synced Oct 21, 2026, 6:09 PM EDT
Completed Not applicable Interventional Results available

One-Lung Ventilation in the Morbidly Obese Patient: Comparison of Double Lumen Versus Bronchial Blockers

NCT00813176
View directory record Official record
Conditions
Obesity
Interventions
Double Lumen Endotracheal Tube, Arndt Bronchial Blocker
Device
Lead sponsor
Javier H Campos
Other
Eligibility
18 Years to 99 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 4, 2018 · Synced Oct 21, 2026, 6:09 PM EDT
Not listed Phase 3 Interventional

Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers

NCT02130310
View directory record Official record
Conditions
Chronic Venous Leg Ulcers
Interventions
CureXcell®, Placebo injection
Biological · Other
Lead sponsor
Macrocure Ltd.
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
28
States / cities
Mesa, Arizona • Phoenix, Arizona • Carlsbad, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2015 · Synced Oct 21, 2026, 6:09 PM EDT
Completed Phase 2 Interventional Results available

Evaluating Ventricular Arrhythmia in Subjects With Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy-Defibrillator

NCT02104583
View directory record Official record
Conditions
Ventricular Arrhythmia
Interventions
Eleclazine, Placebo to match eleclazine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
37
States / cities
Mesa, Arizona • Long Beach, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Oct 21, 2026, 6:09 PM EDT
Completed Not applicable Interventional Results available

Safety and Clinical Performance of the Protecta ICD and CRT-D

NCT00982397
View directory record Official record
Conditions
Tachyarrhythmias, Heart Failure, Ventricular Dysfunction
Interventions
Protecta VR-ICD, Protecta DR-ICD or CRT-D
Device
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
Not listed
Enrollment
2,770 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
29
States / cities
Birmingham, Alabama • Mesa, Arizona • Fort Smith, Arkansas + 26 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 21, 2026, 6:09 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Ascorbic Acid, Corticosteroids, and Thiamine in Sepsis (ACTS) Trial

NCT03389555
View directory record Official record
Conditions
Sepsis, Septic Shock, Metabolic Disturbance
Interventions
vitamin C, vitamin B1, hydrocortisone, Normal saline
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
13
States / cities
Phoenix, Arizona • Boston, Massachusetts • Cambridge, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Oct 21, 2026, 6:09 PM EDT